ALENDRONATE, ETIDRONATE, RISEDRONATE, RALOXIFENE, TERIPARATIDE AND STRONTIUM RANELATE
NICE Appraisals
Primary prevention
TA160 Alendronate, etidronate, risedronate, raloxifene and strontium ranelate for the primary prevention of osteoporotic fragility fractures in postmenopausal women (January 2011)
Secondary prevention
TA161 Alendronate, etidronate, risedronate, raloxifene, strontium ranelate and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women (January 2011)
DSU Reports
Exploring the effect of the efficacy of strontium ranelate in preventing hip fracture in relation to cost-effectiveness (October 2010) (Report academic in confidence)
Comments on appraisal of strontium ranelate for the prevention of osteoporotic fragility fractures in postmenopausal women (September 2010)
Analyses of the cost effectiveness of pooled alendronate and risedronate, compared with strontium ranelate, raloxifene, etidronate and teriparatide (September 2006)
The clinical effectiveness and cost effectiveness of prevention and treatment of osteoporosis (December 2003)